7 results about "Gastro enteritis" patented technology

Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3′R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3′-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.

The present invention discloses a novel chalcone compound, a preparation method, a pharmaceutical composition, and applications thereof, belonging to the field of pharmaceutical technology. The chalcone compound (±)-Lupulusone A provided by the present invention has not been reported to date. Experimental results show that the chalcone compound provided by the present invention has significant anti-inflammatory activity against lipopolysaccharide-induced RAW 264.7 cells, significantly superior to the positive drug dexamethasone. It can be used to develop drugs for treating various inflammatory-related diseases, including but not limited to pneumonia, hepatitis, nephritis, arthritis, conjunctivitis, gastroenteritis, metabolic syndrome, diabetes, cancer, etc.

Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3′R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3′-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.

The invention discloses a preparation method of a coix seed and tartary buckwheat tea bag. The tea bag comprises the following components in parts by weight: 4-6 parts of coix seeds, 4-6 parts of tartary buckwheat, 0.5-0.75 part of stevia rebaudiana, 0.8-1.2 parts of Chinese wolfberry fruits, 1-1.5 parts of cape jasmine fruits and 1-1.5 parts of honeysuckle flowers. Certain auxiliary effects are achieved on hyperlipidemia, enterogastritis, gastrointestinal indigestion and diabetes mellitus; various active substances are contained, so that liver detoxification can be promoted, and liver health can be protected; therefore, the tea is suitable for most people to drink.

The invention discloses a medicine capable of treating diseases and resisting aging and a preparation method thereof. The medicine comprises the following components in parts by mass: 9 parts of American ginseng, 9 parts of saffron crocus, 9 parts of antelope horn, 9 parts of cornu cervi pantotrichum, 15 parts of radix rehmanniae, 15 parts of radix rehmanniae preparata, 15 parts of Chinese yam, 15 parts of semen cuscutae, 15 parts of mantis egg-case, 15 parts of pulp of dogwood fruit, 15 parts of rhizoma anemarrhenae, 15 parts of cortex lycii radicis, 16 parts of rhizoma alismatis, 12 parts of gastrodia elata, 12 parts of cistanche, 20 parts of astragalus membranaceus, 20 parts of mulberry, 20 parts of eclipta, 20 parts of rheum officinale, 20 parts of tendril-leaved fritillary bulb, 50 parts of caulis spatholobi, 16 parts of semen allii tuberosi, 30 parts of fructus lycii and 16 parts of glossy privet fruit. The preparation method comprises the following steps: soaking in yellow rice wine, decocting to obtain liquid medicine, and concentrating to prepare the soft capsule. The preparation method comprises the following steps of: adding a mixture of 9 parts of deer-horn glue, 9 parts of tortoise-plastron glue and 0.3 part of musk into the lixivium of 16 parts of cherokee rose fruit. The medicine disclosed by the invention can be used for treating diseases such as three highs, heart diseases, chronic gastroenteritis, senile osteoarthritis and the like, and has an effect of prolonging the life of a human body.

The invention relates to the technical field of pet food preparation, in particular to a basic ration additive for relieving gastroenteritis and a preparation method and application thereof. The catalyst comprises the following substances in parts by weight: 80-85 parts of a carrier; 5-10 parts of a yeast cell wall extract; 1-3 parts of enzymolysis oat fiber; 0.5 to 1 part of apple fiber; 0.1 to 0.3 part of ascorbic acid; 0.5 to 1 part of a prebiotic oligosaccharide compound; and 0.5-1 part of an antioxidant. Enzymatic oat fibers, apple fibers, ascorbic acid and prebiotic oligosaccharide compounds for improving intestinal tracts are added into the basic ration for cats to achieve a synergistic effect, so that diarrhea and intestinal inflammation symptoms of the cats during enterogastritis can be relieved.

Nutraceutical compositions and methods of their use in treating Caliciviridae family viruses are provided. The viruses can be norovirus or sapovirus. An exemplary nutraceutical composition includes Fagopyrum dibotrys extract. Another nutraceutical composition for treating viral gastroenteritis includes 5, 7, 3′, 4′-tetrahydroxyflavan-3-ol C4-C8 dimers, quercetin, rutin, or a combination thereof. The nutraceutical compositions inhibit or reduce entry of Caliciviridae family viruses into intestinal epithelial cells of the subject.